The online version of this article (doi:10.1186/s12885-017-3176-x) contains supplementary material, which is available to authorized users.
Median age at diagnosis of patients with chronic lymphocytic leukemia (CLL) is > 70 years. However, the majority of clinical trials do not reflect the demographics of CLL patients treated in the community. We examined treatment patterns, outcomes, and disease-related mortality in patients ≥ 75 years with CLL (E-CLL) in a real-world setting.
The Connect® CLL registry is a multicenter, prospective observational cohort study, which enrolled 1494 adult patients between 2010–2014, at 199 US sites. Patients with CLL were enrolled within 2 months of initiating first line of therapy (LOT1) or a subsequent LOT (LOT ≥ 2). Kaplan–Meier methods were used to evaluate overall survival. CLL- and infection-related mortality were assessed using cumulative incidence functions (CIF) and cause-specific hazards. Logistic regression was used to develop a classification model.
A total of 455 E-CLL patients were enrolled; 259 were enrolled in LOT1 and 196 in LOT ≥ 2. E-CLL patients were more likely to receive rituximab monotherapy (19.3 vs. 8.6%; p < 0.0001) and chemotherapy-alone regimens (p < 0.0001) than younger patients. Overall and complete responses were lower in E-CLL patients than younger patients when given similar regimens. With a median follow-up of 3 years, CLL-related deaths were higher in E-CLL patients than younger patients in LOT1 (12.6 vs. 5.1% p = 0.0005) and LOT ≥ 2 (31.3 vs. 21.5%; p = 0.0277). Infection-related deaths were also higher in E-CLL patients than younger patients in LOT1 (7.4 vs. 2.7%; p = 0.0033) and in LOT ≥ 2 (16.2 vs. 11.2%; p = 0.0786). A prognostic score for E-CLL patients was developed: time from diagnosis to treatment < 3 months, enrollment therapy other than bendamustine/rituximab, and anemia, identified patients at higher risk of inferior survival. Furthermore, higher-risk patients experienced an increased risk of CLL- or infection-related death (30.6 vs 10.3%; p = 0.0006).
CLL- and infection-related mortality are higher in CLL patients aged ≥ 75 years than younger patients, underscoring the urgent need for alternative treatment strategies for these understudied patients.
The Connect CLL registry was registered at clinicaltrials.gov: NCT01081015 on March 4, 2010.
Additional file 1: List of site-specific IRBs. (DOCX 22 kb)12885_2017_3176_MOESM1_ESM.docx
Additional file 2: Table S1. CR and ORR of patients < 75 years versus patients ≥ 75 years enrolled in LOT1 by specific therapy. (DOCX 17 kb)12885_2017_3176_MOESM2_ESM.docx
Additional file 3: Table S2. Cause-specific hazards analysis of prognostic indicators for OS. (DOCX 18 kb)12885_2017_3176_MOESM3_ESM.docx
Additional file 4: Table S3. Incidence of serious adverse events of any grade in enrolled patients by therapy and age group. (DOCX 18 kb)12885_2017_3176_MOESM4_ESM.docx
Additional file 5: Table S4. Incidence of serious adverse events of grade ≥ 3 in enrolled patients by therapy and age group. (DOCX 18 kb)12885_2017_3176_MOESM5_ESM.docx
Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873–83. CrossRefPubMed
Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Smith SM, Shanafelt TD, Evens AM, et al. The impact of race, ethnicity, age, and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive surveillance, epidemiology, and end results analysis in the modern era. Leuk Lymphoma. 2014;55:2778–84. CrossRefPubMed
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood. 2008;111:5446–56. CrossRefPubMedPubMedCentral
Charlson ME, Sax FL, MacKenzie CR, Braham RL, Fields SD, Douglas Jr RG. Morbidity during hospitalization: can we predict it? J Chronic Dis. 1978;40:705–12. CrossRef
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81. CrossRef
Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection, vol. 2. Montreal: Proceedings of the 14th International Joint Conference on Artificial Intelligence (IJCAI); 1995. p. 1137–45.
DaCosta BS, Small A, Becker LK, Reyes CM. Differences in treatment patterns and health care costs among non-Hodgkin’s lymphoma and chronic lymphocytic leukemia patients receiving rituximab in the hospital outpatient setting versus the office/clinic setting. J Cancer Ther. 2014;5:208–16. CrossRef
The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–90. CrossRef
- Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States
Christopher R. Flowers
David L. Grinblatt
Mark A. Weiss
Matthew S. Davids
Arlene S. Swern
E. Dawn Flick
Jeff P. Sharman
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II